Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $650

Benzinga · 2d ago
Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $550 to $650.